RESUMO
BACKGROUND: Many individuals develop excess skin (ES) following massive weight loss (MWL). Patient-reported outcomes demonstrate that abdominal ES negatively impacts perceived physical function which is improved by abdominal body contouring surgery (ABCS). However, the effect of ABCS on objective measures of physical function is unknown. OBJECTIVES: The aim of this study was to examine the impact of ABCS on objective measures of physical function in individuals who have undergone MWL. METHODS: Patients who have undergone MWL with abdominal ES (grade, ≥2) underwent the following physical function assessments: 9-item modified physical performance test (mPPT), chair stand, star excursion balance test (SEBT), timed up and go (TUG), modified agility T test, and 6-minute walk test (6-MWT). Perception of physical exertion and BODY-Q questionnaire scales were also collected. Nonsurgical controls (nâ =â 21) and those who had undergone ABCS (nâ =â 6) after the first visit performed a second physical function assessment 8 to 12 weeks later to allow for postoperative healing. RESULTS: No ceiling or floor effect was detected for any physical function measure. The intraclass correlation coefficient was 0.78 (95% CI, 0.44, 0.91) for the mPPT and >0.80 for all other measures. The effect sizes were 0.74 (75% CI, 0.19, 1.28) for the mPPT, 0.54 (75% CI, 0.00, 1.08) for the SEBT, -0.63 (75% CI, -1.17, -0.09) for the modified agility T test, and 0.79 (75% CI, 0.24, 0.13) for the 6-MWT. CONCLUSIONS: The mPPT and tests involving dynamic balance, agility, and walking were reliable and showed medium to large effect sizes, suggesting that these tests may be sensitive to change following ABCS.
Assuntos
Contorno Corporal , Humanos , Estudos Prospectivos , Cicatrização , Redução de PesoRESUMO
PURPOSE: Soluble fibre beneficially affects metabolism but whether it can augment the reductions in glycemia induced through intensive weight management has not been extensively studied. Our objective was to examine the adjunct effect of the soluble viscous fibre PGX® on glycemic control in adults with type 2 diabetes (T2D) enrolled in a year-long medically supervised weight management program. METHODS: In a placebo-controlled, double-blind study, 290 adults with overweight/obesity and T2D were randomized to receive PGX (15-20 g/day) or isocaloric placebo (rice flour, 6.4-8.6 g/day) as an adjunct to intensive weight management for 52 weeks. The primary outcome was change in glycemic control (HbA1c). Other outcome measures included weight loss, blood lipids, blood pressure, cytokines and fecal microbiota. RESULTS: Compared to baseline HbA1c in PGX (7.2 ± 1.1%) and placebo (7.0 ± 0.9%) groups, there was a significant reduction at 16 and 26 weeks, however, only PGX showed a significant absolute reduction of 0.23% at 52 weeks; there were no between-group differences in HbA1c. At 52 weeks, only PGX significantly decreased body weight compared to baseline and reduced waist circumference at all time points. Compared to baseline, only PGX showed a significant reduction in LDL cholesterol at 16 and 26 weeks. PGX significantly increased the relative abundance of Collinsella, Parabacteroides and Roseburia. CONCLUSION: Adding PGX to a weight management program for individuals with T2D provides a sustained reduction in HbA1c compared to placebo. Improvements in other metabolic outcomes suggest that PGX may be a promising adjunct to weight loss programs in patients with T2D. CLINICAL TRIAL: This trial was registered at ClinicalTrials.gov as NCT01644201.
Assuntos
Diabetes Mellitus Tipo 2 , Programas de Redução de Peso , Adulto , Glicemia , Diabetes Mellitus Tipo 2/terapia , Fibras na Dieta , Método Duplo-Cego , Controle Glicêmico , Humanos , Obesidade/terapiaRESUMO
OBJECTIVES: To assess vitamin D status of pediatric patients with Crohn's disease (CD) and to compare their serum 25-hydroxyvitamin D (s-25OHD) with established cutoffs and assess whether 6 months of supplementation with 2000 IU/d, vs 400 IU/d, would reduce the group prevalence of vitamin D below these cutoffs. STUDY DESIGN: Subjects 8-18 years (n = 83) with quiescent CD were randomized to either 400 or 2000 IU vitamin D3/d for 6 months. RESULTS: Baseline mean ± SD s-25OHD was 24 ± 8 ng/mL; 13 subjects (16%) had an s-25OHD <16 ng/mL, 27 (33%) < 20 ng/mL, and 65 (79%) < 30 ng/mL. There was no significant difference between groups in achieving the cutoffs of 16 ng/mL or 20 ng/mL at 6 months; however, only 35% of the 400 IU group achieved the greater cutoff of 30 ng/mL compared with 74% in the 2000 IU group (P < .001). Baseline adjusted mean s-25OHD concentrations at 6 months were 9.6 ng/mL (95% CI 6.0-13.2, P < .001) greater in the 2000 IU than the 400 IU group. Disease activity was not affected by supplement dose. Few subjects exceeded safety marker cutoffs, and this did not differ by dose. CONCLUSIONS: At baseline, a high proportion of patients had a mean s-25OHD >20 ng/mL. 2000 IU vitamin D3/d is more effective in raising s-25OHD concentrations to > 30 ng/mL in children with CD than 400 IU/d, but both treatments were equally effective at achieving 16 or 20 ng/mL.
Assuntos
Doença de Crohn/sangue , Suplementos Nutricionais , Vitamina D/análogos & derivados , Adolescente , Criança , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Masculino , Fatores de Tempo , Vitamina D/administração & dosagem , Vitamina D/sangueRESUMO
The objective of this research was to determine the dose-response effects of a palatable, viscous and gel forming fibre, PolyGlycopleX(®) (PGX(®)), [(α-D-glucurono-α-manno-ß-D-manno-ß-D-gluco), (α-Lgulurono-ß-D mannurono), (ß-D-gluco-ß-D-mannan)] on satiety, and to gain insight into the underlying mechanisms that lead to appetite inhibition. Healthy subjects (n = 10), aged between 20.3 and 29.2 years, consumed PGX(®), in granular form at 2.5, 5.0 and 7.5 g, and a 5g inulin control, with a standard breakfast. The PGX(®) doses of 2.5 and 7.5 g mixed with water at the start of breakfast increased satiety (iAUC of 140.0 and 157.7, P = 0.025 and 0.001, respectively) compared to the control. The most effective dose (7.5g) was palatable and corresponded to a 34% increase in fullness, measured using a visual analogue scale and incremental area under the curve, and resulted in a delayed postprandial glycaemic response when compared with the control.
Assuntos
Alginatos/administração & dosagem , Glicemia/metabolismo , Fibras na Dieta/administração & dosagem , Polissacarídeos Bacterianos/administração & dosagem , Saciação/efeitos dos fármacos , Adulto , Alginatos/farmacologia , Apetite , Área Sob a Curva , Fibras na Dieta/farmacologia , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Humanos , Polissacarídeos Bacterianos/farmacologia , Período Pós-Prandial , Adulto JovemRESUMO
The novel polysaccharide (NPS) PolyGlycopleX (PGX) has been shown to reduce glycemia. Pharmacological treatment with sitagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, also reduces glycemia by increasing glucagon-like peptide-1 (GLP-1). Our objective was to determine if using NPS in combination with sitagliptin reduces hyperglycemia in Zucker diabetic fatty (ZDF) rats more so than either treatment alone. Male ZDF rats were randomized to: 1) cellulose/vehicle [control (C)]; 2) NPS (5% wt:wt)/vehicle (NPS); 3) cellulose/sitagliptin [10 mg/(kg · d) (S)]; or 4) NPS (5%) + S [10 mg/(kg · d) (NPS+S)]. Glucose tolerance, adiposity, satiety hormones, and mechanisms related to DPP4 activity and hepatic and pancreatic histology were examined. A clinically relevant reduction in hyperglycemia occurred in the rats treated with NPS+S (P = 0.001) compared with NPS and S alone. Blood glucose, measured weekly in fed and feed-deprived rats and during an oral glucose tolerance test, was lower in the NPS+S group compared with all other groups (all P = 0.001). At wk 6, glycated hemoglobin was lower in the NPS+S group than in the C and S (P = 0.001) and NPS (P = 0.06) groups. PGX (P = 0.001) and S (P = 0.014) contributed to increased lean mass. Active GLP-1 was increased by S (P = 0.001) and GIP was increased by NPS (P = 0.001). Plasma DPP4 activity was lower in the NPS+S and S groups than in the NPS and C groups (P = 0.007). Insulin secretion and ß-cell mass was increased with NPS (P < 0.05). NPS alone reduced LDL cholesterol and hepatic steatosis (P < 0.01). Independently, NPS and S improve several metabolic outcomes in ZDF rats, but combined, their ability to markedly reduce glycemia suggests they may be a promising dietary/pharmacological co-therapy for type 2 diabetes management.
Assuntos
Alginatos/farmacologia , Hiperglicemia/tratamento farmacológico , Polissacarídeos Bacterianos/farmacologia , Pirazinas/farmacologia , Saciação/efeitos dos fármacos , Triazóis/farmacologia , Animais , Glicemia/análise , Diabetes Mellitus Tipo 2/tratamento farmacológico , Dipeptidil Peptidase 4/sangue , Inibidores da Dipeptidil Peptidase IV/farmacologia , Combinação de Medicamentos , Peptídeo 1 Semelhante ao Glucagon/sangue , Teste de Tolerância a Glucose , Insulina/sangue , Insulina/metabolismo , Secreção de Insulina , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Masculino , Obesidade/tratamento farmacológico , Ratos , Ratos Zucker , Fosfato de SitagliptinaRESUMO
The development of lower-glycaemic index (GI) foods requires simple, palatable and healthy strategies. The objective of the present study was to determine the most effective dose of a novel viscous fibre supplement (PGX®) to be added to starchy foods to reduce their GI. Healthy subjects (n 10) consumed glucose sugar (50 g in water × 3) and six starchy foods with a range of GI values (52-72) along with 0 (inert fibre), 2.5 or 5 g granular PGX® dissolved in 250 ml water. GI testing according to ISO Standard 26,642-2010 was used to determine the reduction in GI. PGX® significantly reduced the GI of all six foods (P < 0.001), with an average reduction of 19 % for the 2.5 g dose and 30 % for the 5 g dose, equivalent to a reducing the GI by 7 and 15 units, respectively. Consuming small quantities of the novel functional fibre PGX®, mixed with water at the start of a meal, is an effective strategy to reduce the GI of common foods.
Assuntos
Alginatos/uso terapêutico , Dieta , Fibras na Dieta/uso terapêutico , Suplementos Nutricionais , Índice Glicêmico , Hiperglicemia/prevenção & controle , Polissacarídeos Bacterianos/uso terapêutico , Adulto , Alginatos/administração & dosagem , Alginatos/efeitos adversos , Glicemia , Pão/efeitos adversos , Estudos Cross-Over , Dieta/efeitos adversos , Carboidratos da Dieta/efeitos adversos , Fibras na Dieta/administração & dosagem , Fibras na Dieta/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Combinação de Medicamentos , Fast Foods/efeitos adversos , Feminino , Humanos , Hiperglicemia/sangue , Masculino , Polissacarídeos Bacterianos/administração & dosagem , Polissacarídeos Bacterianos/efeitos adversos , Período Pós-Prandial , Amido/efeitos adversos , Viscosidade , Adulto JovemRESUMO
INTRODUCTION: The purpose of this study was to investigate the efficacy and safety of L-theanine as an aid to the improvement of objectively measured sleep quality in a population of 98 male children formally diagnosed with attention-deficit/hyperactivity disorder (ADHD). METHODS: A randomized, double-blind, placebo-controlled trial was conducted involving boys, ages 8-12 years, who had been previously diagnosed with ADHD. An experienced physician confirmed the diagnosis of ADHD in each subject. Randomization was stratified based upon current use of stimulant medication to ensure an equal distribution of stimulant/non-stimulant treated subjects into active and placebo treated groups. Participants consumed two chewable tablets twice daily (at breakfast and after school), with each tablet containing 100 mg of L-theanine (total 400 mg daily Suntheanine®, Taiyo Kagaku, Yokkaichi, Japan) or identical tasting chewable placebo for six weeks. Subjects were evaluated for five consecutive nights using wrist actigraphy at baseline, and again at the end of the six-week treatment period. The Pediatric Sleep Questionnaire (PSQ) was completed by parents at baseline and at the end of the treatment period. RESULTS: Actigraph watch data findings indicated that boys who consumed L-theanine obtained significantly higher sleep percentage and sleep efficiency scores, along with a non-significant trend for less activity during sleep (defined as less time awake after sleep onset) compared to those in the placebo group. Sleep latency and other sleep parameters were unchanged. The PSQ data did not correlate significantly to the objective data gathered from actigraphy, suggesting that parents were not particularly aware of their children's sleep quality. L-theanine at relatively high doses was well tolerated with no significant adverse events. CONCLUSIONS: This study demonstrates that 400 mg daily of L-theanine is safe and effective in improving some aspects of sleep quality in boys diagnosed with ADHD. Since sleep problems are a common co-morbidity associated with ADHD, and because disturbed sleep may be linked etiologically to this disorder, L-theanine may represent a safe and important adjunctive therapy in childhood ADHD. Larger, long-term studies looking at the wider therapeutic role of this agent in this population are warranted.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Glutamatos/uso terapêutico , Transtornos do Sono-Vigília/tratamento farmacológico , Actigrafia , Administração Oral , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Criança , Terapias Complementares , Método Duplo-Cego , Glutamatos/administração & dosagem , Humanos , Masculino , Transtornos do Sono-Vigília/complicações , Inquéritos e Questionários , Resultado do TratamentoRESUMO
OBJECTIVE: Health benefits of viscous fiber intake are well established; nevertheless few effective and palatable preparations are available. The objective of the study therefore was to determine palatability and effectiveness of escalating doses of PGX, a novel viscous polysaccharide (NVP), in reducing postprandial glycemia when added to a liquid and a solid meal. DESIGN: Two open-label, randomized, controlled trials were undertaken. SETTING: Glycemic Index Laboratories, Inc, Toronto, Ontario, Canada. SUBJECTS: Two groups of 10 healthy subjects each (group 1: 5 M, 5 F; 35.6 +/- 13.2 y; 24.6 +/- 2.1 kg/m(2); and group 2: 3 M, 7 F; 33.5 +/- 11.1 y; 26.3 +/- 5.2 kg/m(2)) were studied. INTERVENTIONS: Zero, 2.5, 5, and 7.5 g of NVP were added to a glucose drink (group 1) or to white bread and margarine (WB + Marg) (group 2). Subjects repeated glucose control (group 1) or WB control (group 2) 3 times to allow calculation of the glycemic index (GI). Measures of Outcomes: Palatability of foods and capillary blood glucose concentrations were measured fasting and at 15, 30, 45, 60, 90, and 120 minutes after the start of the meal. RESULTS: Addition of NVP to the meal reduced blood glucose incremental areas under the curve irrespective of dose, reaching significance at the 7.5 g dose when added to glucose (p < 0.01), and at the 5 and 7.5 g doses when added to WB + Marg (p < 0.001). The GI values of glucose with 0, 2.5, 5, or 7.5 g of NVP were (mean +/- standard error of the mean [SEM]) 100.0 +/- 0.0, 83.7 +/- 9.0, 77.7 +/- 8.2, and 72.5 +/- 5.9, respectively; the GI of the WB alone, or of WB + Marg, with 0, 2.5, 5, or 7.5 g of NVP was 71.0 +/- 0.0, 66.8 +/- 3.0, 47.5 +/- 5.9, 37.3 +/- 5.9, and 33.9 +/- 3.6, respectively. CONCLUSION: Addition of NVP to different food matrices is highly effective in lowering the glycemic index of a food in a dose-responsive manner.
Assuntos
Glicemia/metabolismo , Carboidratos da Dieta/metabolismo , Fibras na Dieta/farmacologia , Índice Glicêmico , Polissacarídeos/farmacologia , Adulto , Análise de Variância , Área Sob a Curva , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Polissacarídeos/administração & dosagem , Período Pós-Prandial , Viscosidade , Adulto JovemRESUMO
BACKGROUND: Viscous soluble dietary fiber has been demonstrated to reduce postprandial glycemia and may promote satiety. PolyGlycopleX (PGX) is a highly viscous polysaccharide manufactured by reacting glucomannan with other soluble polysaccharides using a proprietary process (EnviroSimplex). The resulting polysaccharide (alpha-D-glucurono-alpha-D-manno-beta-D-manno-beta-D-glucan, alpha-L-gulurono-beta-D-mannuronan, beta-D-gluco-beta-D-mannan, alpha-D-glucurono-alpha-D-manno-beta-D-manno-beta-D-gluco, alpha-L-gulurono-beta-D-mannurono, beta-D-gluco-beta-D-mannan) is a novel entity with the highest viscosity and water-holding capacity of currently known fibers. MATERIALS AND METHODS: A total of 29 sedentary overweight or obese adults (23 women; six men), ages 20-65 with a body mass index (BMI) range of 25 kg/m(2) to 36 kg/m(2) participated in a clinical weight-loss program. PGX (5 g) was consumed with 500 mL water, 5-10 minutes before each meal, 2-3 times daily for 14 weeks. RESULTS: Significant reductions were observed (p less than 0.05) in weight (-5.79 +/- 3.55 kg), waist circumference (-12.07 +/- 5.56 cm), and percentage body fat (-2.43 +/- 2.39 percent) compared to baseline values. In addition, subjects employing PGX had a significant reduction of 19.26 percent (n=17; p less than 0.05) and 25.51 percent (n=16; p less than 0.05) in total and LDL plasma cholesterol values, respectively, at the end of the study period. CONCLUSION: The consumption of PGX in concert with lifestyle modifications may be a useful strategy for weight loss in overweight and obese individuals.
Assuntos
Estilo de Vida , Mananas/administração & dosagem , Obesidade/dietoterapia , Polissacarídeos/administração & dosagem , Redução de Peso , Adulto , Idoso , Peso Corporal , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Viscosidade , Adulto JovemRESUMO
BACKGROUND: The relationship of dietary fiber to overall health is of great importance, as beneficial effects have been demonstrated with the use of fiber from diverse sources, some traditional, other novel. PolyGlycopleX (PGX) is a unique proprietary product composed of three water-soluble polysaccharides, that when processed using novel technology give rise to a final product - a soluble, highly viscous functional fiber. METHODS: Because of its potential use in food and dietary supplements, a randomized, double-blind, placebo controlled clinical study was conducted to evaluate the tolerance to PGX ingestion for 21 days, to a maximum dose level of 10 g per day, in healthy male and female volunteers. The main objective of the study was to evaluate the overall gastrointestinal (GI) tolerance, while secondary objectives were to evaluate possible changes in hematological, biochemical, urinary and fecal parameters. RESULTS: Results show that PGX is well tolerated as part of a regular diet with only mild to moderate adverse effects, similar to those seen with a moderate intake of dietary fiber in general, and fruits and vegetables. Because PGX is a highly viscous, functional fiber, it also demonstrates several physiological responses including, but not limited to maintaining healthy total and LDL cholesterol and uric acid levels.
Assuntos
Alginatos/administração & dosagem , Fibras na Dieta/administração & dosagem , Polissacarídeos Bacterianos/administração & dosagem , Adolescente , Adulto , Alginatos/efeitos adversos , Fibras na Dieta/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Trato Gastrointestinal/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Polissacarídeos Bacterianos/efeitos adversosRESUMO
BACKGROUND: This study was designed to evaluate the safety of PolyGlycopleX (PGX), a novel viscous dietary polysaccharide (fiber), when administered to Sprague Dawley(R) rats in the diet for 90 days. METHODS: Groups of ten male and ten female rats each consumed PGX mixed in the diet at levels of 0, 1.25, 2.5 or 5.0% for 90 days, then evaluated for toxicological effects on parameters that included neuromotor activity, body weight, clinical chemistry, urinalysis, hematology, and histopathology. RESULTS: Mean body weight, mean feed consumption and food efficiency in the treated groups were generally comparable to controls for both male and female rats. No changes were noted in neuromotor behavior, and histopathological analysis revealed no significant changes between treated and control animals. There were no differences in mean organ weight, organ-to-body weight or organ-to-brain weight values between controls and treated animals. Decreased red blood cell count occurred in the high dose males and increases in aspartate and alanine aminotransferase enzyme levels and triglycerides, while significant decreases in serum sodium, potassium and chloride concentrations were observed in the females fed 5.0% PGX. However, the decreased mineral concentrations may be the result of significantly increased urinary volume in both males and females at the high dose, with a concomitant decrease in urinary specific gravity (males and females) and protein concentration (females). These results were within historical control values, did not correlate with any histopathological changes, and were not considered adverse. CONCLUSION: The results indicate a no observed adverse effect level (NOAEL) for PGX at 5.0% of the diet, corresponding to an average daily intake of 3219 and 3799 mg/kg bw/day in male and female rats, respectively.
Assuntos
Peso Corporal/efeitos dos fármacos , Fibras na Dieta/toxicidade , Tamanho do Órgão/efeitos dos fármacos , Polissacarídeos/toxicidade , Administração Oral , Animais , Análise Química do Sangue , Fibras na Dieta/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Masculino , Nível de Efeito Adverso não Observado , Polissacarídeos/administração & dosagem , Ratos , Ratos Sprague-Dawley , Testes de Toxicidade Crônica , Urinálise , Urina/químicaRESUMO
BACKGROUND: Vitamin D supplementation is recommended for breastfed infants. Maternal supplementation beginning in gestation is a potential alternative, but its efficacy in maintaining infant 25-hydroxyvitamin D [25(OH)D] concentration after birth is unknown. OBJECTIVES: We determined the effect of 3 doses of maternal vitamin D supplementation beginning in gestation and continued in lactation on infant serum 25(OH)D and compared the prevalence of infant serum 25(OH)D cutoffs (>30, >40, >50, and >75 nmol/L) by dose at 8 wk of age. DESIGN: Pregnant women (n = 226) were randomly allocated to receive 10, 25, or 50 µg vitamin D3/d from 13 to 24 wk of gestation until 8 wk postpartum, with no infant supplementation. Mother and infant blood was collected at 8 wk postpartum. RESULTS: At 8 wk postpartum, mean [nmol/L (95% CI)] infant 25(OH)D at 8 wk was higher in the 50-µg/d [75 (67, 83)] than in the 25-µg/d [52 (45, 58)] or 10-µg/d [45 (38, 52)] vitamin D groups (P < 0.05). Fewer infants born to mothers in the 50-µg/d group had a 25(OH)D concentration <30 nmol/L (indicative of deficiency) than infants in the 25- and 10-µg/d groups, respectively (2% compared with 16% and 43%; P < 0.05). Fewer than 15% of infants in the 10- or 25-µg/d groups achieved a 25(OH)D concentration >75 nmol/L compared with 44% in the 50-µg/d group (P < 0.05). Almost all infants (â¼98%, n = 44) born to mothers in the 50-µg/d group achieved a 25(OH)D concentration >30 nmol/L. At 8 wk postpartum, mean maternal 25(OH)D concentration was higher in the 50-µg/d [88 (84, 91)] than in the 25-µg/d [78 (74, 81)] or 10-µg/d [69 (66, 73)] groups (P < 0.05). CONCLUSIONS: Maternal supplementation beginning in gestation with 50 µg vitamin D3/d protects 98% of unsupplemented breastfed infants against 25(OH)D deficiency (<30 nmol/L) to at least 8 wk, whereas 10 or 25 µg vitamin D/d protects only 57% and 84% of infants, respectively.
Assuntos
Calcifediol/sangue , Colecalciferol/administração & dosagem , Suplementos Nutricionais , Lactação , Fenômenos Fisiológicos da Nutrição Materna , Deficiência de Vitamina D/prevenção & controle , Adulto , Colúmbia Britânica/epidemiologia , Calcifediol/metabolismo , Cálcio/sangue , Desenvolvimento Infantil , Colecalciferol/efeitos adversos , Colecalciferol/deficiência , Colecalciferol/uso terapêutico , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Feminino , Sangue Fetal/química , Humanos , Hipercalcemia/sangue , Hipercalcemia/epidemiologia , Hipercalcemia/etiologia , Recém-Nascido , Análise de Intenção de Tratamento , Lactação/metabolismo , Masculino , Cooperação do Paciente , Gravidez , Complicações na Gravidez/sangue , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/etiologia , Prevalência , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/congênito , Deficiência de Vitamina D/epidemiologiaRESUMO
Our primary objective was to determine whether administering the viscous and fermentable polysaccharide PolyGlycopleX (PGX) with metformin (MET) or sitagliptin/metformin (S/MET) reduces hyperglycemia in Zucker diabetic fatty (ZDF) rats more so than monotherapy of each. Glucose tolerance, adiposity, satiety hormones and mechanisms related to dipeptidyl peptidase 4 activity, gut microbiota and, hepatic and pancreatic histology were examined. Male ZDF rats (9-10 weeks of age) were randomized to: i) cellulose/vehicle (control, C); ii) PGX (5% wt/wt)/vehicle (PGX); iii) cellulose/metformin (200 âmg/kg) (MET); iv) cellulose/S/MET (10 âmg/kg+200 âmg/kg) (S/MET); v) PGX (5%)+MET (200â mg/kg) (PGX+MET); vi) cellulose/sitagliptin/MET (5%)+(10â mg/kg+200 âmg/kg) (PGX+S/MET) for 6 weeks. PGX+MET and PGX+S/MET reduced glycemia compared with C and singular treatments (P=0.001). Weekly fasted and fed blood glucose levels were lower in PGX+MET and PGX+S/MET compared with all other groups at weeks 4, 5, and 6 (P=0.001). HbA1c was lower in PGX+S/MET than C, MET, S/MET, and PGX at week 6 (P=0.001). Fat mass was lower and GLP1 was higher in PGX+S/MET compared with all other groups (P=0.001). ß-cell mass was highest and islet degeneration lowest in PGX+S/MET. Hepatic lipidosis was significantly lower in PGX+S/MET compared with PGX or S/MET alone. When combined with PGX, both MET and S/MET markedly reduce glycemia; however, PGX+S/MET appears advantageous over PGX+MET in terms of increased ß-cell mass and reduced adiposity. Both combination treatments attenuated diabetes in the obese Zucker rat.
Assuntos
Alginatos/administração & dosagem , Diabetes Mellitus Tipo 2/prevenção & controle , Hiperglicemia/tratamento farmacológico , Hipoglicemiantes/administração & dosagem , Metformina/administração & dosagem , Polissacarídeos Bacterianos/administração & dosagem , Pirazinas/administração & dosagem , Triazóis/administração & dosagem , Animais , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patologia , Progressão da Doença , Combinação de Medicamentos , Quimioterapia Combinada , Humanos , Hiperglicemia/metabolismo , Hiperglicemia/patologia , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Masculino , Ratos , Ratos Zucker , Fosfato de SitagliptinaRESUMO
Many of the health benefits associated with dietary fiber are attributed to their fermentation by microbiota and production of short chain fatty acids (SCFA). The aim of this study was to investigate the fermentability of the functional fiber PolyGlyopleX® (PGX®) in vitro. A validated dynamic, computer-controlled in vitro system simulating the conditions in the proximal large intestine (TIM-2) was used. Sodium hydroxide (NaOH) consumption in the system was used as an indicator of fermentability and SCFA and branched chain fatty acids (BCFA) production was determined. NaOH consumption was significantly higher for Fructooligosaccharide (FOS) than PGX, which was higher than cellulose (p = 0.002). At 32, 48 and 72 h, acetate and butyrate production were higher for FOS and PGX versus cellulose. Propionate production was higher for PGX than cellulose at 32, 48, 56 and 72 h and higher than FOS at 72 h (p = 0.014). Total BCFA production was lower for FOS compared to cellulose, whereas production with PGX was lower than for cellulose at 72 h. In conclusion, PGX is fermented by the colonic microbiota which appeared to adapt to the substrate over time. The greater propionate production for PGX may explain part of the cholesterol-lowering properties of PGX seen in rodents and humans.
Assuntos
Alginatos/farmacologia , Fibras na Dieta/farmacologia , Ácidos Graxos/biossíntese , Intestino Grosso/efeitos dos fármacos , Polissacarídeos Bacterianos/farmacologia , Butiratos/metabolismo , Combinação de Medicamentos , Fermentação , Humanos , Concentração de Íons de Hidrogênio , Intestino Grosso/metabolismo , Intestino Grosso/microbiologia , Microbiota , Modelos Biológicos , Propionatos/metabolismo , Hidróxido de Sódio/metabolismoRESUMO
OBJECTIVE: Evidence supports the role of dietary fiber in improving metabolic health. PolyGlycopleX (PGX), a viscous functional polysaccharide improves lipidemia and glycemia in healthy adults. Our objective was to examine the effects of PGX on risk factors associated with the metabolic syndrome in Japanese adults with abdominal obesity. DESIGN AND METHODS: Sixty four subjects assigned to 14 weeks of 15 g day(-1) of PGX or placebo were assessed in a randomized, double-blind, placebo-controlled, parallel group trial. At week 0 and 14, primary outcome measures were serum lipids, abdominal adiposity, glucose tolerance and blood pressure. RESULTS: Total and LDL cholesterol were reduced at week 14 with PGX but not placebo (P < 0.05). The reduction in waist circumference at week 14 was greater with PGX versus placebo (P < 0.05). In females, abdominal visceral fat was decreased to a greater extent with PGX versus placebo (P < 0.05). While glucose tolerance worsened with placebo over time, PGX reduced glucose total area under the curve from week 0 to 6 (P = 0.039). Serum concentrations of resistin and IL6 increased slightly in placebo and decreased slightly with PGX . CONCLUSIONS: PGX is a functional fiber that shows promise in reducing risk factors related to the metabolic syndrome in Japanese adults with abdominal obesity.
Assuntos
Glicemia/metabolismo , Colesterol/sangue , Fibras na Dieta/uso terapêutico , Gordura Intra-Abdominal/metabolismo , Síndrome Metabólica/prevenção & controle , Obesidade Abdominal/dietoterapia , Polissacarídeos/uso terapêutico , Adiposidade , Adulto , Idoso , Povo Asiático , LDL-Colesterol/sangue , Fibras na Dieta/farmacologia , Método Duplo-Cego , Feminino , Intolerância à Glucose/sangue , Intolerância à Glucose/etiologia , Intolerância à Glucose/prevenção & controle , Humanos , Hipoglicemiantes/farmacologia , Hipoglicemiantes/uso terapêutico , Hipolipemiantes/farmacologia , Hipolipemiantes/uso terapêutico , Interleucina-6/sangue , Masculino , Síndrome Metabólica/etiologia , Síndrome Metabólica/metabolismo , Pessoa de Meia-Idade , Obesidade Abdominal/metabolismo , Polissacarídeos/farmacologia , Resistina/sangue , Fatores Sexuais , Viscosidade , Circunferência da Cintura , Adulto JovemRESUMO
In this open, clinically based, weight modification program, we determined in six sedentary obese adults (five women; one male; age range 30-62 years) that the combination of a modified calorie diet plus PGX® meal replacement and PGX® supplementation resulted in a significant reduction in several cardiovascular risk factors over a 12-week time period. This included a significant improvement in lipids (-0.98 mmol/l LDL-C), reduction in average weight (-9.2 kg), mean reduction in fat (-4.1%) and an increase in fat-free mass (2.8%).
Assuntos
Composição Corporal/efeitos dos fármacos , Restrição Calórica , Doenças Cardiovasculares/prevenção & controle , Fibras na Dieta/uso terapêutico , Obesidade/dietoterapia , Redução de Peso/efeitos dos fármacos , Programas de Redução de Peso , Tecido Adiposo/efeitos dos fármacos , Adulto , Alginatos/farmacologia , Alginatos/uso terapêutico , Compartimentos de Líquidos Corporais/efeitos dos fármacos , Doenças Cardiovasculares/etiologia , LDL-Colesterol/sangue , Dieta Redutora , Fibras na Dieta/farmacologia , Suplementos Nutricionais , Feminino , Ácido Glucurônico/farmacologia , Ácido Glucurônico/uso terapêutico , Ácidos Hexurônicos/farmacologia , Ácidos Hexurônicos/uso terapêutico , Humanos , Masculino , Mananas/farmacologia , Mananas/uso terapêutico , Pessoa de Meia-Idade , Obesidade/sangue , Polissacarídeos Bacterianos/farmacologia , Polissacarídeos Bacterianos/uso terapêutico , Fatores de Risco , Comportamento SedentárioRESUMO
Inadequate dietary fiber intake is common in modern diets, especially in children. Epidemiological and experimental evidence point to a significant association between a lack of fiber intake and ischemic heart disease, stroke atherosclerosis, type 2 diabetes, overweight and obesity, insulin resistance, hypertension, dyslipidemia, as well as gastrointestinal disorders such as diverticulosis, irritable bowel disease, colon cancer, and cholelithiasis. The physiological effects of fiber relate to the physical properties of volume, viscosity, and water-holding capacity that the fiber imparts to food leading to important influences over the energy density of food. Beyond these physical properties, fiber directly impacts a complex array of microbiological, biochemical, and neurohormonal effects directly through modification of the kinetics of digestion and through its metabolism into constituents such as short chain fatty acids, which are both energy substrates and important enteroendocrine ligands. Of particular interest to clinicians is the important role dietary fiber plays in glucoregulation, appetite, and satiety. Supplementation of the diet with highly functional fibers may prove to play an important role in long-term obesity management.
RESUMO
Viscous soluble fibers have been shown to reduce risk factors associated with type 2 diabetes and cardiovascular disease. The novel functional fiber, PolyGlycopleX (PGX) (InovoBiologic Inc, Calgary, Alberta, Canada) displays greater viscosity than other currently identified soluble fibers. The objective of this study was to determine if PGX lowers serum and hepatic triglycerides (TGs) in a high-sucrose-fed rat model. In this rodent model, feeding a high-sucrose diet consistently increases serum TGs. We hypothesized that consumption of PGX would attenuate hypertriglyceridemia and reduce hepatic steatosis compared with cellulose in rats fed a high-sucrose background diet. Male Sprague-Dawley rats were fed diets containing 65% sucrose and supplemented with either 5% cellulose (control) or 5% PGX (wt/wt) for 43 weeks. At study termination, serum insulin and TGs, hepatic steatosis, and hepatocellular injury were assessed. Body weight increased over time in both groups, but weight gain was attenuated in rats fed PGX vs cellulose in weeks 2 through 22 (P < .05). Serum TGs did not differ from baseline for the first half of the study but consistently increased in the cellulose group thereafter. PolyGlycopleX significantly reduced serum TG to near-baseline levels. At study termination, rats fed PGX had significantly lower hepatic steatosis scores (measured by Sudan black staining) compared with rats fed cellulose. Hepatocellular injury scores did not differ between the groups. In conclusion, PGX reduced serum TG and lipid accumulation in the liver of sucrose-fed rats. Further examination of its potential as a fiber supplement aimed at lessening the burden of hepatic steatosis is warranted.
Assuntos
Alginatos/administração & dosagem , Fibras na Dieta/administração & dosagem , Sacarose Alimentar/efeitos adversos , Fígado Gorduroso/tratamento farmacológico , Polissacarídeos Bacterianos/administração & dosagem , Triglicerídeos/sangue , Animais , Glicemia/análise , Combinação de Medicamentos , Fígado Gorduroso/induzido quimicamente , Hipertrigliceridemia/tratamento farmacológico , Insulina/sangue , Fígado/metabolismo , Masculino , Modelos Animais , Ratos , Ratos Sprague-Dawley , Aumento de PesoRESUMO
AIMS: The effects of the novel water soluble, viscous fiber complex PolyGlycopleX® [(α-D-glucurono-α-D-manno-ß-D-manno-ß-D-gluco), (α-L-gulurono-ß-D mannurono), ß-D-gluco-ß-D-mannan (PGX®)] on body weight, food consumption, glucose, insulin, and glucagon-like peptide (GLP-1) levels were determined in Zucker diabetic rats (ZDFs). Such fibers are thought to improve glycemic control through increased GLP-1 induced insulin secretion. MAIN METHODS: ZDFs were treated 12 weeks with normal rodent chow supplemented with cellulose (control, inert fiber), inulin or PGX® at 5% wt/wt and effects on body weight, glycemic control, and GLP-1 determined. KEY FINDINGS: In the fed state, PGX® reduced blood glucose compared to the other groups from week 5 until study termination while insulin was significantly elevated when measured at week 9, suggesting an insulin secretagogue effect. Fasting blood glucose was similar among groups until 7-8 weeks when levels began to climb with a modest reduction caused by PGX®. An oral glucose tolerance test in fasted animals (week 11) showed no change in insulin sensitivity scores among diets, suggesting an insulinotropic effect for PGX® rather than increased insulin sensitivity. PGX® increased plasma levels of GLP-1, while HbA(1c) was markedly reduced by PGX®. Body weights were not changed despite a significant reduction in food consumption induced by PGX® up to week 8 when the PGX®-treated group showed an increase in body weight despite a continued reduction in food consumption. SIGNIFICANCE: PGX® improved glycemic control and reduced protein glycation, most likely due to the insulin secretagogue effects of increased GLP-1.
Assuntos
Alginatos/administração & dosagem , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Peptídeo 1 Semelhante ao Glucagon/sangue , Hiperglicemia/dietoterapia , Insulina/sangue , Polissacarídeos Bacterianos/administração & dosagem , Ração Animal , Animais , Peso Corporal/efeitos dos fármacos , Celulose/administração & dosagem , Combinação de Medicamentos , Ingestão de Alimentos/efeitos dos fármacos , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/metabolismo , Hiperglicemia/sangue , Masculino , Ratos , Ratos ZuckerRESUMO
Dietary fiber can reduce insulin resistance, body weight, and hyperlipidemia depending on fiber type, water solubility, and viscosity. PolyGlycopleX(®) (PGX(®)) is a natural, novel water soluble, non-starch polysaccharide complex that with water forms a highly viscous gel compared to other naturally occurring dietary fiber. We determined the effect of dietary PGX(®) vs. cellulose and inulin on the early development of insulin resistance, body weight, hyperlipidemia, and glycemia-induced tissue damage in young Zucker diabetic rats (ZDFs) in fasted and non-fasted states. ZDFs (5 weeks old) were fed a diet containing 5% (wgt/wgt) cellulose, inulin, or PGX(®) for 8 weeks. Body weight, lipids, insulin, and glucose levels were determined throughout the study and homeostasis model assessment (HOMA) was used to measure insulin sensitivity throughout the study in fasted animals. At study termination, insulin sensitivity (oral glucose tolerance test, OGTT) and kidney, liver, and pancreatic histopathology were determined. Body weight and food intake were significantly reduced by PGX(®) vs. inulin and cellulose. Serum insulin in fasted and non-fasted states was significantly reduced by PGX(®) as was non-fasted blood glucose. Insulin resistance, measured as a HOMA score, was significantly reduced by PGX(®) in weeks 5 through 8 as well as terminal OGTT scores in fed and fasted states. Serum total cholesterol was also significantly reduced by PGX(®). PGX(®) significantly reduced histological kidney and hepatic damage in addition to reduced hepatic steatosis and cholestasis. A greater mass of pancreatic ß-cells was found in the PGX(®) group. PGX(®) therefore may be a useful dietary additive in the control of the development of the early development of the metabolic syndrome.